TY - JOUR
T1 - Needles in a haystack
T2 - Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections
AU - Salmanton-García, Jon
AU - Koehler, Philipp
AU - Kindo, Anupma
AU - Falces-Romero, Iker
AU - García-Rodríguez, Julio
AU - Ráčil, Zdeněk
AU - Chen, Sharon C.A.
AU - Klimko, Nikolai
AU - Desoubeaux, Guillaume
AU - Thompson, George R.
AU - Benítez-Peñuela, Miguel Ángel
AU - Rodríguez, José Yesid
AU - Sheppard, Donald C.
AU - Hoenigl, Martin
AU - Le Govic, Yohann
AU - Badali, Hamid
AU - Baddley, John W.
AU - Chander, Jagdish
AU - Ingram, Paul R.
AU - Pakstis, Diana L.
AU - Mellinghoff, Sibylle C.
AU - Atıcı, Serkan
AU - Cesaro, Simone
AU - Chakrabarti, Arunaloke
AU - Dupont, Damien
AU - González, Gloria M.
AU - Hatvani, Lóránt
AU - Herbrecht, Raoul
AU - Klyasova, Galina
AU - Lass-Flörl, Cornelia
AU - Mareș, Mihai
AU - Mullane, Kathleen
AU - Vinh, Donald C.
AU - Wisplinghoff, Hilmar
AU - Lackner, Michaela
AU - Cornely, Oliver A.
AU - Seidel, Danila
AU - Alexander, Barbara D.
AU - Almagro-Molto, María
AU - Álvarez-Duarte, Eduardo
AU - Avilés-Robles, Martha
AU - Barać, Aleksandra
AU - Chrenková, Vanda
AU - Cornejo-Juárez, Patricia
AU - Desbois-Nogard, Nicole
AU - Fernández-Ruiz, Mario
AU - Figueira, Luis
AU - García-Martínez, Jesús
AU - Gräber, Sandra
AU - Graf, Barbara
AU - Haerter, Georg
AU - Haider, Shariq
AU - Hartman, Pamela
AU - Heinemann, Melina
AU - Ikram, Aamer
AU - Janvier, Frédéric
AU - Jenks, Jeffrey D.
AU - Kauffman, Carol
AU - Krause, Robert
AU - Luong, Me Linh
AU - Malik, Shruti
AU - Marconi, Vincent
AU - Martino, Rodrigo
AU - Mehta, Sanjay R.
AU - Meintker, Lisa
AU - Mocná, Andrea
AU - Morris, Michele I.
AU - Pasqualotto, Alessandro C.
AU - Patel, Atul
AU - Penack, Olaf
AU - Pichon, Nicolas
AU - Pletz, Mathias W.
AU - Seas, Carlos
AU - Sili, Uluhan
AU - Slavin, Monica
AU - Uno, Kenji
AU - Vazquez, Jose A.
AU - Weber, Thomas
AU - Weinbergerova, Barbora
AU - Yilmaz-Karapinar, Deniz
AU - Yilmaz-Semerci, Seda
AU - Yu, Jin
N1 - Funding Information:
SCAC reports grants from MSD Australia, outside the submitted work.
Funding Information:
DCS reports grants from Merck and personal fees from Merck, Astellas, and AVIR, outside the submitted work.
Funding Information:
MH reports grants from Gilead, outside the submitted work.
Funding Information:
RH reports grants from Gilead, Novartis, and Pfizer and personal fees from Astellas, Basilea, Gilead, MSD, Novartis, and Pfizer, outside the submitted work.
Funding Information:
CLF reports grants from Astellas Pharma and Gilead Sciences; personal fees from Angelini, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme; and other support from Astellas Pharma, Basilea, Biomerieux, Gilead Sciences, and Merck Sharp and Dohme, outside the submitted work.
Funding Information:
KM reports grants as a clinical trial investigator from Gilead Sciences, Inc., clinical research grants from Ansun, Astellas, Merck, Rebiotix, Scynexis, and Shire; and consultant fees/honoraria from Chimerix, GlaxoSmithKline, Merck, and Scynexis outside the submitted work.
Funding Information:
DCV reports support from Avir Pharma, Cidara Therapeutics, CSL Behring, and Fonds de la Recherche en Santé du Quebec, during the conduct of the study (salary support), outside the submitted work.
Funding Information:
OAC reports grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, and Scynexis and personal fees from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, F2G, Entasis, Gilead, Grupo Biotoscana, Matinas, MedPace, Menarini Ricerche, Merck/MSD, Nabriva Therapeutics Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics, Scynexis, Seres Therapeutics, and Tetraphase outside the submitted work.
Funding Information:
FungiScope Ⓡ is supported by unrestricted grants of Amplyx Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutics, F2G Ltd., Matinas BioPharma, MSD Sharp & Dohme GmbH, and SCYNEXIS Inc. FungiScope Ⓡ has been supported in the past by unrestricted grants of Astellas Pharma, Gilead Sciences, and Pfizer Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.
AB - Objectives: Emerging invasive fungal infections (IFI) have become a notable challenge. Apart from the more frequently described fusariosis, lomentosporiosis, mucormycosis, scedosporiosis, and certain dematiaceae or yeasts, little is known about extremely rare IFI. Methods: Extremely rare IFI collected in the FungiScopeⓇ registry were grouped as Dematiaceae, Hypocreales, Saccharomycetales, Eurotiales, Dermatomycetes, Agaricales, and Mucorales. Results: Between 2003 and June 2019, 186 extremely rare IFI were documented in FungiScopeⓇ. Dematiaceae (35.5%), Hypocreales (23.1%), Mucorales (11.8%), and Saccharomycetales (11.3%) caused most IFI. Most patients had an underlying malignancy (38.7%) with acute leukemia accounting for 50% of cancers. Dissemination was observed in 26.9% of the patients. Complete or partial clinical response rate was 68.3%, being highest in Eurotiales (82.4%) and in Agaricales (80.0%). Overall mortality rate was 29.3%, ranging from 11.8% in Eurotiales to 50.0% in Mucorales. Conclusions: Physicians are confronted with a complex variety of fungal pathogens, for which treatment recommendations are lacking and successful outcome might be incidental. Through an international consortium of physicians and scientists, these cases of extremely rare IFI can be collected to further investigate their epidemiology and eventually identify effective treatment regimens.
KW - Invasive fungal infections
KW - Mold
KW - Rare
KW - Registry
KW - Yeast
UR - http://www.scopus.com/inward/record.url?scp=85091481893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091481893&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2020.08.015
DO - 10.1016/j.jinf.2020.08.015
M3 - Article
C2 - 32798532
AN - SCOPUS:85091481893
VL - 81
SP - 802
EP - 815
JO - Journal of Infection
JF - Journal of Infection
SN - 0163-4453
IS - 5
ER -